Megan Bock, MD
Urology · Carmel, INNPI 1205356722
Payments from drug & device makers
What this record shows
This record is dominated by grants: $25,000 of the $27,673 with a category attached, or 90.3%. Boston Scientific accounts for 93.8% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $25,734, more than ten times the $36 reported in 2019.
Across 79 payments — averaging $350.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$26K
- Cook Medical LLC$234
- Astellas Pharma US Inc$227
- Sumitomo Pharma America, Inc.$201
- Pfizer$155
- Axonics, Inc.$119
- plus $790 from 22 others
What the payments were for
- Grants$25,00090%
- Food & beverage$2,4899%
- Education$1841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 19 | $25,947 |
| Cook Medical LLC | 2 | $234 |
| Astellas Pharma US Inc | 5 | $227 |
| Sumitomo Pharma America, Inc. | 7 | $201 |
| Pfizer | 9 | $155 |
| Axonics, Inc. | 3 | $119 |
| Ambu Inc. | 2 | $92 |
| Endo Pharmaceuticals Inc. | 3 | $65 |
| Antares Pharma, Inc. | 2 | $65 |
| Tolmar, Inc. | 3 | $60 |
| Myriad Genetic Laboratories, Inc. | 3 | $58 |
| Urovant Sciences Inc | 2 | $47 |
| Sun Pharmaceutical Industries Inc. | 2 | $46 |
| Koelis Inc. | 2 | $38 |
| Johnson & Johnson | 2 | $37 |
| Calyxo, Inc. | 1 | $33 |
| Ferring Pharmaceuticals Inc. | 1 | $28 |
| Coloplast | 1 | $27 |
| Conmed Corporation | 1 | $27 |
| Blue Earth Diagnostics | 1 | $26 |
| Tolmar Pharmaceuticals, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Olympus America Inc. | 1 | $18 |
| Accord Healthcare, Inc. | 1 | $17 |
| Foundation Medicine, Inc. | 1 | $17 |
| Teleflex LLC | 1 | $17 |
| Mission Pharmacal Company | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$25,000
- AMS 700$153
- LITHO 150$151
- AMS 700 CXR RTE KIT$126
How this compares
$27,673 in reported general payments places this provider in the 85th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 29 | $30,719 |
| Estradiol | 51 | $4,022 |
| Tamsulosin Hcl | 167 | $1,568 |
| Potassium Citrate ErPotassium Citrate | 11 | $689 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 34 | $483 |
| Finasteride | 34 | $358 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 14 | $321 |
| Cephalexin | 32 | $173 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $68 |
| Ciprofloxacin Hcl | 14 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $201 | $30,71929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 272 urology providers in Indiana.
Other urology in Carmel
- Alexander TatemCarmel$418K
- Chad ReichardCarmel$400K
- Matthew MellonCarmel$159K
- Jason KovacCarmel$112K
- Kenneth NeyCarmel$55K
- Jeremiah DallmerCarmel$52K
- Scott FarnhamCarmel$30K
- Joshua RingCarmel$13K
- Clinton BahlerCarmel$11K
- Scott PikeCarmel$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.